MetaCap

Inhibrx Biosciences (INBX) vs Novavax (NVAX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Novavax (NVAX) has outperformed Inhibrx Biosciences (INBX) over the past year, gaining 15.5% versus a loss of 17.8%. Novavax is the larger company by market cap ($1.23 billion vs $1.02 billion), about 1.2 times the size, while Inhibrx Biosciences is growing revenue faster (+550.0% vs +64.7%). Novavax converts more of its revenue into profit, with a net margin of 39.2% versus -10773.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INBX-17.82%NVAX+15.46%
+105%+34%-37%
Nov 21, 20251 yearNov 20, 2026
INBX+324.43%NVAX-50.30%
+766%+333%-100%
May 27, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INBX versus NVAX key metrics
MetricINBXNVAX
Share price$68.97$7.47
Market cap$1.02B$1.23B
1-day change-7.21%-3.24%
YTD return-12.70%+11.16%
1-year return-17.82%+15.46%
5-year return—-96.57%
EPS (TTM)$-9.06$-0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.30M$1.12B
Revenue growth (YoY)+550.00%+64.69%
Net income (latest FY)$-140.06M$440.30M
Gross margin—93.50%
Operating margin-10386.54%40.30%
Net margin-10773.46%39.19%
52-week high$155.29$13.39
52-week low$57.30$6.36
Distance from 52-week high-55.59%-44.21%
Analyst consensusnonebuy
Avg. price target upside+286.65%+88.89%
Average volume305.96K6.67M
Shares outstanding14.77M165.01M
Employees109749
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NVAX has outperformed INBX by 33.3 percentage points over the past year.
  • Novavax is more profitable, keeping 39.2 cents of every revenue dollar as net income versus -10773.5 cents for Inhibrx Biosciences.
  • Inhibrx Biosciences grew revenue faster in its latest fiscal year (+550.00% vs +64.69%).

About Inhibrx Biosciences

INBX stock →

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees

About Novavax

NVAX stock →

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees

INBX vs NVAX FAQ

Which is bigger, Inhibrx Biosciences or Novavax?

Novavax (NVAX) is larger, with a market capitalization of $1.23B compared with $1.02B for Inhibrx Biosciences (INBX).

Which stock has performed better over the past year, INBX or NVAX?

NVAX returned +15.46% over the past 12 months, compared with -17.82% for INBX (price return, excluding dividends). Past performance does not predict future results.

Are Inhibrx Biosciences and Novavax in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons